Poliklinikte Kalp Yetersizliği Hastası Takibi ve Tedavisi

Meryem Aktoz

Follow-up and Treatment of Patients with Heart Failure in Policlinic

Year 2010, Volume: 2010 Issue: 1, 57 - 62, 01.01.2010

Abstract

Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder. Heart failure (HF) is a major and growing public health problem in the whole world, in part because of increasing numbers of patients with HF due to better treatment and salvage of patients with acute myocardial infarction earlier in life. Also heart failure is a major clinical syndrome that can cause increasing cardiovascular mortality and morbidity. The number of HF deaths has increased steadily despite advances in treatment. This article includes follow-up of the policlinic patients with heart failure and treatment of them. Kalp yetersizliği kalbin yapısal ve fonksiyonel bozukluğuna neden olabilen karmaşık klinik bir sendromdur. Kalp yetersizliği tüm dünyada büyük bir halk sağlığı problemi haline gelmiştir. Bunun nedeni daha iyi tedavi alan kalp yetersizliği hastalarının ve daha erken yaşlarda akut miyokard infarktüsünden kurtulan hastaların sayısının artmasıdır. Aynı zamanda kalp yetersizliği tüm dünyada kardiyovasküler mortalite ve morbiditeye neden olan önemli bir klinik tablodur. Tedavideki gelişmelere rağmen kalp yetersizliğine bağlı ölümler sürekli artmaktadır. Bu makale kalp yetersizliği hastasının poliklinik takibi ve tedavisi ile ilgili güncel bilgileri içermektedir.

Keywords

Heart failure, follow-up, treatment

References

Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart fai- lure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
Evangelista LS, Dracup K. A closer look at compliance research in heart failure patients in the last decade. Prog Cardiovasc Nurs 2000;15:97-103.
van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non- compliance in patients with heart failure; how can we manage it? Eur J Heart Fail 2005;7:5-17.
Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 2004;116:693-706.
Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
Effect of metoprolol CR/XL in chronic heart failu- re: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in pati- ents with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9.
Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to deter- mine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-recep- tor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.